(Q38104612)

English

Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials

scientific article published on 07 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

inflammatory bowel diseases

0 references

0 references

0 references

opportunistic infection

1 reference

based on heuristic

inferred from title

Alexander C. Ford

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Laurent Peyrin-Biroulet

2

object named as

Laurent Peyrin-Biroulet

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

0 references

publication date

7 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

108

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1268-1276

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Systematic review: Infliximab therapy in ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Adalimumab safety in global clinical trials of patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Infliximab prevents Crohn's disease recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.138

21 January 2018

Identifiers

10.1038/AJG.2013.138

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38104612&oldid=1741846265"